<DOC>
	<DOC>NCT01104766</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.</brief_summary>
	<brief_title>Safety and Efficacy of Cariprazine in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Patients who have provided informed consent prior to any study specific procedures Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID) Patients with normal physical examination, laboratory, vital signs,and/ or electrocardiogram (ECG) Patients with a DSMIVTR diagnosis of Schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Acute Schizophrenia</keyword>
	<keyword>Psychotropic Drugs</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Dopamine Agents</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>